A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN027)
Phase of Trial: Phase III
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Gefapixant (Primary)
- Indications Cough
- Focus Adverse reactions; Therapeutic Use
- Sponsors Afferent Pharmaceuticals; Merck Sharp & Dohme
- 02 Apr 2018 Planned primary completion date changed from 13 Nov 2019 to 20 Sep 2019.
- 15 Mar 2018 Planned End Date changed from 5 Sep 2020 to 6 Jul 2020.
- 15 Mar 2018 Status changed from not yet recruiting to recruiting.